Bottom line
XBI vs FBTAX: the short answer
XBI (State Street(R) SPDR(R) S&P(R) Biotech ETF) and FBTAX (Fidelity Advisor Biotechnology Fund) are quite different portfolios: only about 21% of their top holdings (by weight) are shared.
XBI is cheaper at 0.35% vs 0.94% — a difference of $59 a year per $10,000 invested.
Over five years, FBTAX returned +6.4% a year vs −2.7% for XBI (reporting dates differ).
Updated Nov 19, 2026
XBI vs FBTAX side by side
| XBI | FBTAX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | Fidelity |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.35% | 0.94% |
| Annual cost per $10k | $35 | $94 |
| 10-yr cost on $10k (prospectus) | $443 | $1,663 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +35.8% | +31.5% |
| 5-yr return (annualized) | −2.7% | +6.4% |
| 10-yr return (annualized) | +5.8% | +7.7% |
| Best quarter | +44.4% | +30.3% |
| Worst quarter | −26.2% | −27.8% |
| Net assets (fund) | $10.7B | $2.2B |
| Number of holdings | 161 | 129 |
| Portfolio turnover | 71% | 54% |
| Returns as of | Dec 31, 2025 | Sep 30, 2026 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XBI | FBTAX | Difference |
|---|---|---|---|
| 2025 | +35.8% | +39.6% | −3.7% |
| 2024 | +1.1% | +5.3% | −4.2% |
| 2023 | +7.5% | +10.7% | −3.2% |
| 2022 | −25.8% | −8.0% | −17.8% |
| 2021 | −20.5% | −3.6% | −17.0% |
| 2020 | +48.2% | +32.2% | +16.0% |
| 2019 | +32.2% | +25.7% | +6.5% |
| 2018 | −14.9% | −3.8% | −11.1% |
| 2017 | +43.7% | +25.8% | +17.9% |
| 2016 | −15.4% | −23.6% | +8.2% |
Source: Fund prospectus bar charts
Holdings overlap
7 of XBI's top 25 holdings also appear in FBTAX's top 25.
| Holding | XBI | FBTAX |
|---|---|---|
| Moderna Inc | 1.41% | 1.60% |
| Oruka Therapeutics Inc | 1.38% | 3.24% |
| Revolution Medicines Inc | 1.20% | 3.00% |
| Vaxcyte Inc | 1.19% | 1.97% |
| Dianthus Therapeutics Inc | 1.18% | 3.55% |
| Natera Inc | 1.16% | 1.43% |
| Cogent Biosciences Inc | 1.14% | 3.25% |
Source: SEC Form N-PORT
XBI top 10
- State Street Global Advisors — 5.87%
- Apogee Therapeutics Inc — 1.49%
- Moderna Inc — 1.41%
- Twist Bioscience Corp — 1.41%
- Oruka Therapeutics Inc — 1.38%
- Kymera Therapeutics Inc — 1.36%
- Viking Therapeutics Inc — 1.30%
- Praxis Precision Medicines Inc — 1.29%
- Erasca Inc — 1.27%
- Revolution Medicines Inc — 1.20%
FBTAX top 10
- Abbvie Inc — 14.71%
- Gilead Sciences Inc — 5.70%
- Spyre Therapeutics Inc — 3.83%
- Alnylam Pharmaceuticals Inc — 3.62%
- Dianthus Therapeutics Inc — 3.55%
- Cogent Biosciences Inc — 3.25%
- Oruka Therapeutics Inc — 3.24%
- Insmed Inc — 3.05%
- Revolution Medicines Inc — 3.00%
- Argenx Se — 3.00%
FAQ
What is the difference between XBI and FBTAX?
Which is cheaper, XBI or FBTAX?
Should I own both XBI and FBTAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.